Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Comparative effectiveness and safety of upadacitinib, abrocitinib and dupilumab in treatment-resistant prurigo nodularis

View through CrossRef
Abstract Background Real-world data comparing dupilumab vs. Janus kinase (JAK)1 inhibitors for refractory prurigo nodularis (PN) are limited. Objectives To compare the effectiveness and safety of dupilumab, abrocitinib and upadacitinib in refractory PN. Methods We conducted a retrospective cohort study of adults with refractory prurigo nodularis (PN). This was defined as no response to at least two systemic therapies, Peak Pruritus Numerical Rating Scale (PP-NRS) ≥ 7 and at least 20 nodules. Patients received dupilumab 300 mg every 2 weeks (n = 12), abrocitinib 200 mg daily (n = 8) or upadacitinib 30 mg daily (two doses of 15 mg, n = 8). Follow-up assessments were conducted at weeks 12 (n = 28), 24 (n = 22) and 36 (n = 15). Primary outcomes were changes in PP-NRS and nodule count. Secondary outcomes included changes in Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS) and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) scores. Results Patients receiving dupilumab were older and had a longer disease duration and higher IgE levels (all P ≤ 0.002). By month 6, a ≥ 4-point reduction in PP-NRS was achieved by 56% of patients on dupilumab, 86% on abrocitinib and 100% on upadacitinib. Nodule reduction by ≥ 50% was seen in 11%, 100% and 100%, respectively. DLQI ≥ 9-point improvement was seen in 33%, 86% and 83%, respectively. HADS scores decreased in all groups, mostly so with upadacitinib. Adverse events included acne (n = 4), creatinine kinase elevation (n = 3), injection-site reaction (n = 2) and herpes zoster (n = 2). No cases of major adverse cardiovascular events, venous thromboembolism, malignancy, serious infection, death or discontinuation occurred. Conclusions In a small, imbalanced multicentre cohort, JAK1 inhibitors showed faster itch relief and greater lesion clearance signals than dupilumab, with meaningful improvements in quality of life.
Title: Comparative effectiveness and safety of upadacitinib, abrocitinib and dupilumab in treatment-resistant prurigo nodularis
Description:
Abstract Background Real-world data comparing dupilumab vs.
Janus kinase (JAK)1 inhibitors for refractory prurigo nodularis (PN) are limited.
Objectives To compare the effectiveness and safety of dupilumab, abrocitinib and upadacitinib in refractory PN.
Methods We conducted a retrospective cohort study of adults with refractory prurigo nodularis (PN).
This was defined as no response to at least two systemic therapies, Peak Pruritus Numerical Rating Scale (PP-NRS) ≥ 7 and at least 20 nodules.
Patients received dupilumab 300 mg every 2 weeks (n = 12), abrocitinib 200 mg daily (n = 8) or upadacitinib 30 mg daily (two doses of 15 mg, n = 8).
Follow-up assessments were conducted at weeks 12 (n = 28), 24 (n = 22) and 36 (n = 15).
Primary outcomes were changes in PP-NRS and nodule count.
Secondary outcomes included changes in Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS) and Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) scores.
Results Patients receiving dupilumab were older and had a longer disease duration and higher IgE levels (all P ≤ 0.
002).
By month 6, a ≥ 4-point reduction in PP-NRS was achieved by 56% of patients on dupilumab, 86% on abrocitinib and 100% on upadacitinib.
Nodule reduction by ≥ 50% was seen in 11%, 100% and 100%, respectively.
DLQI ≥ 9-point improvement was seen in 33%, 86% and 83%, respectively.
HADS scores decreased in all groups, mostly so with upadacitinib.
Adverse events included acne (n = 4), creatinine kinase elevation (n = 3), injection-site reaction (n = 2) and herpes zoster (n = 2).
No cases of major adverse cardiovascular events, venous thromboembolism, malignancy, serious infection, death or discontinuation occurred.
Conclusions In a small, imbalanced multicentre cohort, JAK1 inhibitors showed faster itch relief and greater lesion clearance signals than dupilumab, with meaningful improvements in quality of life.

Related Results

Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis
Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis
Dupilumab is a humanized monoclonal antibody which specifically targets interleukin-4/interleukin-13 receptor and is primarily indicated for the treatment of atopic dermatitis, alt...
Increased β‐endorphin and autotaxin in patients with prurigo
Increased β‐endorphin and autotaxin in patients with prurigo
AbstractObjectivesPrurigo is a treatment‐resistant inflammatory disease of unknown etiology. Persistent and severe itch is a major and important clinical symptom, but pathological ...
Recent advances in treatment of prurigo nodularis
Recent advances in treatment of prurigo nodularis
AbstractPrurigo nodularis is a chronic skin condition which has significant negative impacts on the psychosocial function and quality of life of affected patients. It is a heteroge...
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
ImportancePatients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event...
Primerjalna književnost na prelomu tisočletja
Primerjalna književnost na prelomu tisočletja
In a comprehensive and at times critical manner, this volume seeks to shed light on the development of events in Western (i.e., European and North American) comparative literature ...
Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis
Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis
AbstractPurposeThe patterns of dupilumab use, the first systemic drug approved for the treatment of atopic dermatitis (AD), is not well understood in the context of off‐label syste...
Expressions of Interleukin-4 and Interleukin-5 in Nodular Prurigo and Pruritic Papular Lesions
Expressions of Interleukin-4 and Interleukin-5 in Nodular Prurigo and Pruritic Papular Lesions
Highlights:1. An examination of IL-4 and IL-5 expressions in nodular prurigo and pruritic papular eruption is crucial for enhancing the effectiveness of biological agent therapy, s...

Back to Top